Sep 04, 2019
The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies. Opdivo, leading drug of Bristol-Myers Squibb approv...
Read More...
Aug 24, 2018
Hepato Cellular Carcinoma (HCC) Not all deadly battles are lost. Some are won too.It is without the slightest doubt that the ones won are the typical examples of smart management, involving implementation of prudent steps, guided by the knowledge of every nook and corner. Undoubtedly, these examples not only serve ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper